Garsorasib, a KRAS G12C inhibitor, with or without cetuximab, an EGFR antibody, in colorectal cancer cohorts of a phase II trial in advanced solid tumors with KRAS G12C mutation by Dan-Yun Ruan, Hao-Xiang Wu, Ye Xu, Pamela N. Munster, Yanhong Deng, Gary Richardson, Dong Yan, Myung-Ah Lee, Keun-Wook Lee, Hongming Pan, Steven Hager, Xingya Li, Shaozhong Wei, Xinfang Hou, Craig Underhill, Michael Millward, Ina Nordman, Jingdong Zhang, Jianzhen Shan, Guohong Han, Jaspreet Grewal, Shirish M. Gadgeel, Rachel E. Sanborn, Seok Jae Huh, Xiaohua Hu, Yihong Zhang, Ziyong Xiang, Laisheng Luo, Xiaoxi Xie, Zhe Shi, Yaolin Wang, Ling Zhang, Feng Wang, Rui-Hua Xu

Get full text